Table 3.
Treatment and outcome of pediatric patients with TA-TMA
| No | CNI | Treatment of CNI | Episodes of TPE | Episodes of Ritux | Other treatments | Efficacy | Outcome | Died of TMA | Time from diagnosis to death (days) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CsA | Withdrawal | 5 | 0 | LMWH | Invalid | Died | Yes | 14 |
| 2 | CsA | Reduction | 4 | 0 | LMWH | Valid | Survival | – | – |
| 3 | CsA | Withdrawal | 4 | 1 | LMWH | Invalid | Died | Yes | 20 |
| 4 | CsA | Withdrawal | 5 | 2 | LMWH | Valid | Survival | – | – |
| 5 | CsA | Withdrawal | 4 | 0 | LMWH | Valid | Died | No | – |
| 6 | CsA | Reduction | 0 | 0 | LMWH | Invalid | Died | Yes | 59 |
| 7 | CsA | Withdrawal | 4 | 1 | LMWH | Valid | Died | No | – |
| 8 | CsA | Reduction | 4 | 0 | Defibrotide | Invalid | Died | Yes | 16 |
| 9 | CsA | Withdrawal | 18 | 3 | LMWH/Eculizumab | Valid | Survival | – | – |
| 10 | CsA | Withdrawal | 14 | 3 | LMWH | Invalid | Died | Yes | 77 |
| 11 | CsA | Withdrawal | 3 | 1 | LMWH | Valid | Died | No | – |
| 12 | FK506 | Withdrawal | 3 | 1 | LMWH | Invalid | Died | Yes | 7 |
| 13 | CsA | Withdrawal | 13 | 0 | LMWH | invalid | Died | Yes | 45 |
| 14 | CsA | Reduction | 4 | 1 | LMWH/Eculizumab | Valid | Died | No | – |
| 15 | CsA | Reduction | 4 | 0 | LMWH | Invalid | Died | Yes | 11 |
| 16 | CsA | Reduction | 4 | 0 | LMWH | Valid | Survival | – | – |
| 17 | CsA | Reduction | 4 | 2 | LMWH | Valid | Survival | – | – |
| 18 | CsA | Withdrawal | 0 | 1 | LMWH | Invalid | Died | Yes | 5 |
| 19 | CsA | Reduction | 3 | 3 | LMWH | Valid | Survival | – | – |
| 20 | CsA | Withdrawal | 0 | 3 | LMWH | Valid | Survival | – | – |
CNI, calcineurin inhibitor; TPE, therapeutic plasmatic exchange; Ritux, rituximab; LMWH, low-molecular-weight heparin